Sanofi completed an investment in InduPro.

Sanofi, a French multinational pharmaceutical company, completed an investment in InduPro, a biotechnology company focused on creating novel protein-based medicines for cancer and autoimmune disease. Financial terms were not disclosed. "We are thrilled to collaborate with Sanofi to advance toward the clinic our bispecific PD-1 agonist program. Sanofi’s know-how and global leadership position in autoimmune and inflammatory diseases make them the ideal partner to bring this exciting first-in-class molecule forward. In addition, we welcome Sanofi’s strategic equity investment into InduPro, which further reinforces the strength of our collaboration,” Prakash Raman, InduPro Chief Executive Officer.